Physician profile
Vu T Ho
NPI 1528071826
$33,115.60
in general payments reported to CMS, 2019-2025
9 companies · $958 in 2025
The $958 reported for 2025 was more than what 85% of Facial Plastic Surgery providers received nationally (typical 2025 total: $271).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $13K · 2020: $6,600 · 2021: $10K · 2022: $392 · 2023: $474 · 2024: $1,227 · 2025: $958.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,634 · Education: $25.35.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,634.04 |
| Education | $25.35 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Galderma Laboratories, L.P. | $30,606.48 | 2019-2025 | Dysport |
| Abbvie INC. | $1,931.82 | 2023-2025 | |
| Allergan, INC. | $244.99 | 2019-2022 | |
| Pacira Pharmaceuticals Incorporated | $121.40 | 2019 | |
| Heron Therapeutics, INC. | $116.71 | 2022 | |
| Lilly USA, LLC | $33.25 | 2019 | |
| Daiichi Sankyo INC. | $29.08 | 2024 | Enhertu |
| Sun Pharmaceutical Industries INC. | $16.23 | 2025 | |
| Bayer Healthcare Pharmaceuticals INC. | $15.64 | 2025 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Vu Ho listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.